Your browser doesn't support javascript.
loading
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan, Sathish; D'Souza, Anita; Scott, Emma; Fraser, Raphael; Davila, Omar; Shah, Nina; Gale, Robert Peter; Kamble, Rammurti; Diaz, Miguel Angel; Lazarus, Hillard M; Savani, Bipin N; Hildebrandt, Gerhard C; Solh, Melhem; Freytes, Cesar O; Lee, Cindy; Kyle, Robert A; Usmani, Saad Z; Ganguly, Siddhartha; Assal, Amer; Berdeja, Jesus; Kanate, Abraham S; Dhakal, Binod; Meehan, Kenneth; Kindwall-Keller, Tamila; Saad, Ayman; Locke, Frederick; Seo, Sachiko; Nishihori, Taiga; Gergis, Usama; Gasparetto, Cristina; Mark, Tomer; Nieto, Yago; Kumar, Shaji; Hari, Parameswaran.
Afiliação
  • Gopalakrishnan S; Health Science North, Sudbury, Ontario, Canada.
  • D'Souza A; CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Scott E; Center for Hematologic Malignancies, The Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
  • Fraser R; CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Davila O; CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Shah N; Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gale RP; Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
  • Kamble R; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
  • Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
  • Lazarus HM; Seidman Cancer Center, Division of Hematology Oncology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
  • Savani BN; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Hildebrandt GC; Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
  • Solh M; The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia.
  • Freytes CO; Texas Transplant Institute, San Antonio, Texas.
  • Lee C; Royal Adelaide Hospital, Adelaide, SA, Australia.
  • Kyle RA; Mayo Clinic Rochester, Rochester, Minnesota.
  • Usmani SZ; Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.
  • Ganguly S; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
  • Assal A; Columbia University Medical Center, New York, New York.
  • Berdeja J; Sarah Cannon BMT Program, Nashville, Tennessee.
  • Kanate AS; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia.
  • Dhakal B; Medical College of Wisconsin, Division of Hematology Oncology; Milwaukee, Wisconsin.
  • Meehan K; Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • Kindwall-Keller T; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia.
  • Saad A; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
  • Locke F; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Seo S; Department of Hematology & Oncology, National Cancer Research Center East, Chiba, Japan.
  • Nishihori T; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Gergis U; Hematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
  • Gasparetto C; Duke University Medical Center, Durham, North Carolina.
  • Mark T; University of Colorado Hospital, Division of Hematology Oncology; Aurora, Colorado.
  • Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Kumar S; Mayo Clinic Rochester, Rochester, Minnesota.
  • Hari P; CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: phari@mcw.edu.
Biol Blood Marrow Transplant ; 25(4): 683-688, 2019 04.
Article em En | MEDLINE | ID: mdl-30579965
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante Autólogo / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante Autólogo / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article